Effects of Jaboticaba (Plinia Cauliflora) Supplementation in Chronic Kidney Disease Patients - Trial NCT06394531
Access comprehensive clinical trial information for NCT06394531 through Pure Global AI's free database. This phase not specified trial is sponsored by Universidade Federal Fluminense and is currently Not yet recruiting. The study focuses on Chronic Kidney Diseases. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Universidade Federal Fluminense
Timeline & Enrollment
N/A
Jul 01, 2024
Jul 01, 2027
Primary Outcome
Primary Outcome Measure,Inflammatory biomarker,Microbiota Composition
Summary
The increase prevalence of chronic kidney disease (CKD) over the years represent a
 significant public health problem. The role of inflammation and oxidative stress in the
 pathophysiology of CKD, as well as progression and comorbidities, is already well
 consolidated. The gut microbiota composition imbalance may also be a risk factor contributing
 to the increased conditions mentioned above, and to uremic toxins release and endotoxemia.
 The literature has indicated the use of bioactive compounds as a nonpharmacological treatment
 strategies for the management of non-communicable diseases (NCDs), such as CKD and its
 complications. In this context, jaboticaba (Plinia Cauliflora) emerges as a potential
 therapeutic approach as it is a source of phenolic compounds, such as anthocyanins,
 flavonols, ellagitannins, and phenolic acids. Such phenolic compounds may have beneficial
 effects in patients with CKD, such as anti-inflammatory, antioxidant, modulation of the
 intestinal microbiota, hypotensive and hypoglycemic effects. These combined effects can help
 manage risk factors and CKD itself, and associated complications. Therefore, this research
 project aims to add scientific knowledge, providing a non-pharmacological therapeutic
 approach to be implemented in clinical practice and in the care of patients with CKD, with
 the aim of modulating inflammation, oxidative stress, microbiota composition, and improving
 the quality of life of these patients. Therefore, this study aims to evaluate the effects of
 jaboticaba (Plinia Cauliflora) supplementation on complications associated with CKD.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06394531
Non-Device Trial